Developments and Next Steps

CARINA L. REBULANANChief, Institution Development Division

Philippine Council for Health Research and DevelopmentDepartment of Science and Technology, Taguig City

Philippines

2

Why a Network?Communicable diseases remain to be the major

cause of deaths throughout the world, and this situation is expected to continue

Desire to enhance progress in product discovery and development in developing countries and contribute to the implementation of the Global Strategy and Plan of Action (GSPA) on Public Health, Innovation and Intellectual Property approved through the World Health Resolution (WHA61.21)

“One ASEAN” by 2015 (ASEAN Secretariat, 2009)

5

ASEAN-NDI Conceptualization

Interest to establish a network for drugs, diagnostics, vaccines and traditional medicines innovation in Asia, was communicated to WHO-TDR

Preparation of proposal for Mapping of Product R&D for Infectious Diseases in ASEAN member states by the Philippines

Approval of Proposal by WHO-TDR

Proposal presentation to the Sub-committee on Biotechnology of the ASEAN Committee on Science and Technology (COST)

ASEAN-COST approval of proposal as ASEAN Initiative

7

The Objectives of ASEAN-NDITo establish the capabilities of the ASEAN member countries for drugs, diagnostics, vaccines, and traditional medicine innovation in the areas of infectious tropical diseases, non-communicable diseases, and preventable diseases due to accidents/traumas

To identify gaps and opportunities in the ASEAN

To create a database of institutions, networks, and initiatives with capacities for innovation

To provide the template for the establishment/future directions of an Asian regional network for innovation in product R&D

Phases of the ASEAN – NDI Development

• Phase 1 – Mapping of Product R&D Landscape for Infectious Tropical Diseases in ASEAN Member Countries

• Phase 2 – ASEAN-NDI Strategic Business Plan (SBP) Development

• Phase 3 – ASEAN-NDI SBP Advocacy• Phase 4 – ASEAN-NDI SBP Launch • Next Steps

PHASE 1: Mapping of Product R&D Landscape for Infectious Tropical Diseases

in ASEAN Member Countries

14

1st ASEAN-NDI Organizational Meeting 21 October 2009, Pan Pacific Hotel Manila, Manila City, Philippines

From left to right: Cheu Sivuthy (Cambodia), Monta Thammasatta (Thailand), Sayyadeth Chanthavong (Lao PDR), Dwi Susilaningsih (Indonesia; representing Judhi Rachmat), Jaime Montoya (Philippines), Bernadette Ramirez (WHO-TDR), Lisa F.P. Ng (Singapore), Yadanar Win Myint (Myanmar), Siti Hanna Muharram (Brunei Darussalam) and Ta Thi Tinh (Vietnam)

Mapping Objectives

to establish the capabilities of the ASEAN member countries for drugs, diagnostics, traditional medicine, and vaccines innovation in infectious tropical diseases;

identify gaps and opportunities in the ASEAN; create a database of institutions, networks, and

initiatives with capacities for innovation; and provide the template for the establishment of an

Asian regional network for innovation in product R&D.

16

Mapping ActivityDecember 2009 – November 2010

Surveys and Key Informant Interviews

Elsevier, Scopus

Data Collection

Survey DatabaseArticles DatabaseWebsite Code Development

Database ConstructionConstant Update on WebsiteContinuous Collection and Correction of Data

Continuous Updating and Uploading of Database

Survey AnalysesLiterature AnalysesCountry Report and Consolidated

Report Writing

Analysis of Data

17

2nd ASEAN-NDI Organizational Meeting06 December 2010, Dusit Thani Hotel Manila, Makati City, Philippines

Presented mapping results per country, and overall regional assessment of product R&D (Country Coordinators, Representatives from MOH and MOST, and WHO-TDR and WPRO)

Reviewed and consolidated the ASEAN R&D landscape mapping results Shared lessons learned from the African Network on Drugs and Diagnostics

Innovation (ANDI) and other regional networks Discussed and agreed on plans for ASEAN NDI including proposed activities

for 2011 – 2012 and funding opportunities for future activities

18

ASEAN-NDI website

Published Tables Blogs

ASEAN-NDI website

Dowloadable contents Database Table

21

Mapping Results

22

Health Research and Social Development

Image Source: World Economic Forum. (2010). The Global Competitiveness Report 2010-2011. Geneva, Switzerland. Map can be retrieved from http://gcr.weforum.org/gcr2010/.

23

Research Productivity

Source: Elsevier. (2010).Scopus. Retrieved July 2010. Accessed at http://scopus.com/.

RESEARCH PRODUCTIVITY AND COLLABORATIONS

24

NATIONAL R&D SPENDING AND MANPOWER

25

CLINICAL TRIALS IN THE REGION

Most clinical trials in the ASEAN region are focused on maladies and conditions other than tropical infectious diseases. Only trials which are currently "open" or "recently completed" in the clinicaltrials.gov database (as of July 2010) were counted.

*ClinicalTrials.gov. Data on numbers of clinical trials per country. Retrieved from http://clinicaltrials.gov/. Accessed J l 2010

26

26

103 Biomedical articles977 Citations182 Inter-country collaborations on infectious diseases

168 Biomedical articles1,044 Citations268 Inter-country collaborations on infectious diseases

12,568 Biomedical articles61,201 Citations5,266 Inter-country collaborations on infectious diseases

186 Biomedical articles619 Citations80 Inter-country collaborations on infectious diseases

318 Biomedical articles2,762 Citations630 Inter-country collaborations on infectious diseases 163 Biomedical

articles486 Citations1,256 Inter-country collaborations on infectious diseases

7,071 Biomedical articles13,143 Citations890 Inter-country collaborations on infectious diseases

12,405 Biomedical articles108, 150 Citations1,256 Inter-country collaborations on infectious diseases

574 Biomedical articles3,415 Citations474 Inter-country collaborations on infectious diseases

1,324 Biomedical articles8014 Citations953 Inter-country collaborations on infectious diseases

Publications

No. of biomedical articles, tations, inter-country ollaborations on infectious seases

per country

27

Collaborations among top 50 most productive institutions for Infectious disease research

Network in ASEAN countries for infectious disease research

Source: Elsevier. (2010).Scopus. Retrieved July 2010. Accessed at http://scopus.com/.

Notes: Collaborations among top 50 most productive institutions (within and outside ASEAN) based on articles on infectious diseases. Size of nodes indicates relative number of articles. Thicker links indicate more instances of collaboration between the two institutions. Blue nodes are institutions in the ASEAN region, while orange nodes represent institutions outside ASEAN.

28

diagnostics researchNetwork in ASEAN countries for diagnostics research

Source: Elsevier. (2010).Scopus. Retrieved July 2010. Accessed at http://scopus.com/.

Notes: Collaborations among top50 most productive institutions (within and outside ASEAN) based on articles on infectious diseases. Size of nodes indicates relative number of articles. Thicker links indicate more instances of collaboration between the two institutions. Blue nodes are institutions in the ASEAN region, while orange nodes represent institutions outside ASEAN.

29

vaccines researchNetwork in ASEAN countries for vaccines research

Source: Elsevier. (2010).Scopus. Retrieved July 2010. Accessed at http://scopus.com/.

Notes: Collaborations among top50 most productive institutions (within and outside ASEAN) based on articles on infectious diseases. Size of nodes indicates relative number of articles. Thicker links indicate more instances of collaboration between the two institutions. Blue nodes are institutions in the ASEAN region, while orange nodes represent institutions outside ASEAN.

CONCLUSIONS FROM PRODUCT R&D LANDSCAPE MAPPING

Initiatives of most ASEAN Member States are mostly similar, thus, encouraging collaboration among countries, and coordination between the public and private sectors to address common health needs.

Though ASEAN member states are in different stages of economic and health development with inadequate investment for product R&D and minimal research output, ASEAN has substantial human resource and institutions that can support the pursuit of R&D products.

The ASEAN region holds a lot of potential in terms of resources for drugs, vaccines, diagnostics and traditional medicine research development.

4

Recommendations drawn from Mapping Activity

Challenges ASEAN-NDI Potential Actions

1 Diverse spectrum of capacity

ASEAN has substantial human resource and institutions that can support the pursuit of R&D on drugs, traditional medicine, diagnostics, and vaccines.

2 Research gap A number of countries can work on the same disease and for the same products (i.e., drugs, vaccines, etc).

3 Reduced coordination among clusters of researchers and innovators

ASEAN member states can facilitate the exchange of expertise, resources and health products as they have been working in other development initiatives.

4 Gaps in R&D investment

Collaborative arrangements with private institutions such as pharmaceutical companies can be worked out.

PHASE 2: ASEAN-NDI Strategic Business Plan (SBP) Development

32

1st ASEAN-NDI Task Force Meeting20 October 2011 Dusit Thani Hotel, Makati City, Philippines

Discussed and agreed on the framework/ initial outline of the draft ASEAN-NDI Strategic Business Plan (SBP) and the timelines for consultations/ discussions by the business development expert with the TF members.

Venue for the discussion of the SBP for ASEAN-NDI, and identification of strategies geared towards the future implementation of collaborations and partnerships within ASEAN on innovation.

33

ASEAN-NDI Strategic Business Plan Reviewvia Videoconferencing

28 February 2012 Asian Institute of Management (AIM), Makati City

Provided the task force members information on the progress of the SBP. Gathered reactions and post clarifications on the questionnaire provided

prior to the meeting which made sure that the SBP would address issues applicable to most of the countries.

2ND Videoconference with ASEAN-NDI Task Force Members10 September 2012 at the Asian Institute of Management, Makati City

Presented and solicited comments on the draft Strategic Business Plan

34

ASEAN-NDI Strategic Business Plan (SBP)

Developed to:

Assess and recommend how ASEAN member states can come together to establish a center for drugs, diagnostics, vaccines, and traditional medicine innovation to address public health threats in ASEAN.

Provide plans for an inter-governmental, collaborative response to the lack of access of poor countries and people to health products.

Create public research and development (R&D) capacity while harnessing the strengths and potential contributions (technical and financial) of the stakeholders including the private sector.

Note: SBP can be downloaded at www.asean-ndi.org

ASEAN-NDI Vision and Mission

Asia’s premier facilitator for innovation in research and development in health products

To address the unmet public health needs of ASEAN nations through the advancement of ASEAN-led health product innovation in the areas of drugs, vaccines, diagnostics and traditional medicine in order to improve health outcomes in the ASEAN region and beyond, and to support sustainable regional economic development.

VISION

MISSION

Diseases to be addressed by ASEAN-NDI: Triple Burden of Disease

Infectious Tropical DiseasesTB, dengue, malaria, Chikingunya, parasitic diseases (Schistosomiasis, Leishmaniasis, etc.) etc.

Non-communicable DiseasesCancer, cardiovascular disease, diabetes, etc.

Preventable Diseases due to Accidents and Trauma

ASEAN-NDI Governance

Governing Council

The responsibilities of the 14-person Governing Council are as follows:

strategy-formulating and policy-making body that ensures the faithful implementation of the vision/mission of ASEAN-NDI

define priorities for cooperation within the scope of the ASEAN Socio-Cultural Community Blueprint, the ASEAN Plan of Action on Science and Technology (APAST), the Hanoi Plan of Action to realize ASEAN Vision 2020, and other documents to be endorsed by ASEAN leaders, Ministers of Science and Technology, or other bodies within ASEAN; and

sustain the network through an advocacy strategy that will engage all stakeholders in supporting its activities, and to mobilizing financial resources for these purposes.

ASEAN-NDI R&D Value Chain

ASEAN-NDI R&D Value Chain

Inclusion of Knowledge ManagementThe core idea of knowledge management—informing, measuring,

and accessing—are the principles governing the platform and process of cooperation within ASEAN-NDI.

Inclusion of Innovation SystemsThese inputs are concerned with infrastructure, human resources,

the knowledge and information systems, and the innovation systems themselves that are at the spirit of innovation communities (IC).

PHASE 3: ASEAN-NDI SBP Advocacy

Meeting with ASEAN AMBASSADORS06 September 2012, Asian Institute of Management, Makati City, Philippines

In coordination with ASEAN Office of the Philippine Department of Foreign Affairs, meeting was held with Philippine-based ASEAN Ambassadors to brief them about ASEAN-NDI and seek assistance in facilitating exchange of information and resources

ASEAN Ambassadors and their representatives committed to coordinate with stakeholders in their home countries

41

ASEAN COST MeetingTagaytay City, Philippines

20-25 May 2013

Per recommendation of the Sub-Committee on Biotechnology, COST approved the Strategic Business Plan of the ASEAN-NDI.

With regard to the request for funding initial ASEAN-NDI activities, the SCB was advised to develop a project proposal that may seek funding support from the ASEAN Science Foundation (ASF), dialogue partners and other sources.

PHASE 4: ASEAN-NDI SBP Launch

ASEAN-NDI Stakeholders MeetingDusit Thani Hotel, Makati City, Philippines

5 June 2013

ASEAN-NDI Stakeholders MeetingDusit Thani Hotel, Makati City, Philippines

5 June 2013

OBJECTIVES

Present the SBP to various Stakeholders in ASEAN as well as key representatives from other regional health R&D innovation networks in China, India, and Africa and in preparation for its presentation to the ASEAN Ministerial Meeting;

Continue advocacy work and ensure buy-in of the SBP among ASEAN stakeholders;

Learn from the best practices/experiences of other regional R&D innovation networks in China and Africa; and

Lay down plans for ASEAN-NDI, including proposed activities for 2013 and funding opportunities for the network.

47

Timelines

ASEAN-NDIConcept Launch

ASEAN-NDIStrategic Business Plan launch

ASEAN-NDIoperation launch

2014

2013

2009

2010-2011

Mapping Activity

Next Steps

51

Next Steps…..• Seek formal approval of ASEAN for

Philippines to host the ASEAN-NDI Secretariat office

• Set up of the Secretariat office• Training of Secretariat and Country Focal

Points• Seek commitment of Heads of States to the

SBP• Establishment of ASEAN-NDI Hub and Spoke

51

Next Steps…..

• Negotiate with potential donors, like the ASEAN Science Foundation, ASEAN dialogue partners and other funding sources

• Organization of the Governing Council• Identify Community of Practice (COP) for

priority disease burdens• Screen initial grants for COPs• Mobilize funds for select COPs

51

Next Steps…..

• Conduct of Capacity-building programsa. training of young scientists for leadership roles

in R&D in the regionb. Involvement of less developed member states

in R&D projects• Collaboration with similar innovation

networks (ANDI, India NDI, China NDI, PAHO Network, WPRO and SEARO Networks, etc.)

Thank You!

3

Burden of Disease

Data source: Gapminder(2007)

• With 8.6% of the world’s population, ASEAN contributes to the 27% of the global burden of infectious and parasitic diseases (WHO,2007).

• National Poverty Lines

• Major factors: lack of market incentives to support health innovations, product R&D, access to essential medicines, fragile health services

2007 life expectancy vs GDP per capita

6

Committee on Science and Technology

8

56

Summary

• Aside from the ASEAN member-states’ commitment to work togethertowards a common goal in the spirit of ‘ASEAN help ASEAN’, theASEAN community has been used to several free trade agreements andharmonization initiatives.

• Hence, establishing a network aimed to strengthen the scientific ties toaddress neglected diseases will not be a herculean task. ASEANmember states can facilitate the exchange of expertise, resources, andhealth products as they have been working in other initiatives for thesocial, political, and economic development of the region.

• This effort is in line with the ASEAN Harmonization expected to takeeffect in 2015.